Orchestra BioMed Holdings R&D Day 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, now you can hear me. Well, welcome to Orchestra BioMed's R&D Day 2026. Welcome to those of you who are not in this beautiful room on a rainy day in New York, and thank you for your patience. The rainy day in New York caused us to do something which is critical to our business, which is adapt and be flexible and solve problems. We have done that. We have a great program today. My name's David Hochman. I'm the chairman and CEO and one of the founders of Orchestra BioMed, and I will also be your emcee. Hopefully this works. Oh, it works, but I'm not seeing that. Today is really focused on R&D, but we do have some fabulous recent updates that I'm going to take a moment just to talk about.
We are, I'm proud to say, funded through 2028, following a very successful oversubscribed public offering that we completed last week. We have some new shareholders in the room. We welcome you guys to the Orchestra BioMed family. We had great support from existing shareholders, and we're super grateful that the $80-plus million in net proceeds from that financing, combined with over $100 million we had at the end of the quarter, have us funded to execute on almost everything we're going to talk about today. That includes having just accomplished the enrollment completion of our BACKBEAT pivotal trial, 349 enrolled patients, and we're now really focused on the follow-up. We'll talk about that. We also learned something really important just this week from the FDA.
We confirmed something we thought, which is that we'll be able to, or our partners at Medtronic will be able to submit this as a PMA supplement. We are excited about the acceleration of the Virtue trial, which is going to be actually our first topic today, and that's happening in real time. Having just come from TCT and having an investigators meeting and a coordinators meeting, we really have some great momentum there. What we're looking ahead at is two years of very significant milestones. We just completed one in terms of enrollment of BACKBEAT. We're looking forward to seeing those results, the primary endpoint results, which hopefully we'll present as a late breaker at HRS in May of 2027.
There is long-term follow-up after that, but exciting regulatory milestones that Medtronic will be able to drive in terms of submission, leading to what we think can be commercialization as early as the first half of 2028 in the U.S., and the second half of that year could see global commercialization. In the same time, we're going to be focused on enrolling the Virtue trial. Our target is the end of next year, 12-month follow-up on that study. A rich landscape of catalysts and milestones. Today, as we talked about, is about R&D, not the business. If you're here, hopefully, you may already be a shareholder, but you've heard about our business model.
You've heard about the arrangements we have in terms of what we can do together with Medtronic, but we really want to focus on the science and the clinical research that has driven these programs. We have a great program. We made some adjustments. We're going to start actually with the deep dive into Virtue SAB with Dr. Allen Jeremias. Darren Sherman's going to lead that program. We're then going to do a deep dive with Vivek Reddy and Marat Fudim into the AVIM program. Unfortunately, we had Dean Kereiakes, one of our co-principal investigators, was supposed to be with us, but unfortunately, is not going to be able to be with us today. But we do have another bonus contributor who is a senior clinical advisor to Orchestra BioMed, Duane Pinto.
Duane is the Chief Medical Officer of one of the most exciting private companies in structural cardiology, JenaValve, and he's spending a little time on the side advising us, and we're really grateful that he'll be here and contributing as well. I'm going to do this without knowing what's behind me because this keeps bouncing. R&D. R&D really starts with unmet needs, and we happen to be focused on, and we're going to dive into specifically how we're focused on helping tackle two of the biggest medical problems there are in the world. Hypertension, which is the number 1 contributing risk factor for death worldwide, and coronary artery disease, which is the leading cause of death. But we have a particular approach to R&D that I want to discuss, and they're consistent across both our programs.
What we first focus on is building on proven foundations, and what you'll see with both of our technologies is we are building on two of the fundamental technologies that have created the fields of interventional cardiology and cardiac rhythm management. With regard to Virtue, balloon angioplasty, with regard to AVIM, the pacemaker. These are technologies that have been in clinical use for upwards of 50 years. What we focus on doing then is creating powerful new capabilities to add to these proven technologies. What we're doing with AVIM is allowing a pacemaker now to be a potent way to immediately and substantially lower blood pressure and treat hypertensive heart disease. With Virtue, we think we are creating a better, superior approach to delivering and extending the release in tissue of a proven drug that will help heal the vessel.
The key to what we do is collaboration. We are realizing the potential of these technologies through collaboration, both with our strategic partners as well as with our research partners. I was here about two years ago, maybe some of you were here. It was a smaller, less well-attended R&D Day event, and it was right when we were getting going with the BACKBEAT trial. One of the things I talked about two years ago is, and this is a great room when you look at the art, you can't see it online, the renaissance that is occurring in the use of these foundational technologies, balloon angioplasty and pacemakers. A renaissance is this beautiful thing of when we look back in time to essentially innovate for the future. That's happening with these foundational technologies. Someone may want to look at this.
It's going in and out. Fortunately, I think I know what I'm talking about. I think we go back with the pacemaker to 1958. We have our colleagues from Medtronic here. I'm going to make them stand up in a minute. But 1958 was the first implant of a pacemaker. For a balloon angioplasty, the first procedure in 1977. Pacemakers are still a fundamental technology. Balloon angioplasty is foundational to everything we do in interventional cardiology, but exciting new things are happening. Pacing, conduction system pacing is really changing the way we think about cardiac pacing therapy and creating a rich, fertile landscape for new treatments like AVIM. Leadless technology, which Medtronic brought first to the market 10 years ago, is entering a very exciting stage of dual-chamber devices.
Actually, we'll talk a little bit about how a single device dual-chamber pacemaker can synergize with our therapy. On the balloon side, we're seeing a renaissance in balloon angioplasty with drug-coated balloons. This renaissance is setting the stage for something. What did the renaissance set the stage for in history? Around the 15th, 16th century, we had all this looking back to the classics to be able to innovate for the future. The renaissance gave birth to something I love, a period in history called the Age of Enlightenment. We've now moved from the last R&D Day to the Age of Enlightenment 2 years later, okay? In that period, we saw the innovations in the renaissance essentially turn into broader and more significant impact in society, where that invention really spread, both through geography and through different parts of society.
In the Age of Enlightenment, the scientific discoveries, things like Copernicus putting the sun at the middle of our solar system became, with Galileo, the birth of astronomy and other sciences. We had the printing press, which suddenly now we can express information everywhere. We see this same theme, okay? We see our technologies enlightening the renaissance that's occurring around the foundation. With AVIM, we're talking about taking cardiac pacing into a whole new area, being able to envision treating hypertension and hypertensive heart disease at the same time as we treat bradycardia, allowing the same device for the same patient to have more impact, while also opening up the potential to treat more patients. The same with Virtue. We're taking proven technology, both the procedure and the drug, and now creating a much better way, in our view, to make that available to tissue, both in the artery and eventually beyond, and we think ultimately improve vessel healing and improve the clinical outcomes for patients.
These are big ideas. Something else happened in the Enlightenment. There was a creation of the symphony orchestra, and that too was driven by innovation and by visionary leadership. It was about new instruments, new training for musicians, new ways of being able to teach music and actually notate music, new ways of thinking about putting groups of musicians together. But then there was this guy, Monteverdi.
If you're a student of classical music, and I'm a real amateur, he had this idea of, "How do I take all of these innovations and bring them together to allow music that we've never heard before, essentially music of a whole another level, but be able to transport that music from city to city, from royal courts eventually to music halls so everyone could enjoy it?" The thing about that symphony orchestra that inspired us is the idea of extraordinary collaboration. I'm going to have to turn to read it because it's one of my favorite quotes. Now I can see it. "What more miraculous creation of mankind is there than the symphony orchestra? A hundred musicians collaborating flawlessly in the creation of a single sonority.
From moment to moment, we tend to take for granted the skill and sensitivity of such a performing organism, and we should take time to marvel afresh that such a joint effort is possible for human beings so rich in communication, beauty, and meaning." A symphony orchestra is really a collection of extraordinary, talented people, the best people in their field, but coming together and sublimating their individuality to create something beautiful together. We are not called Orchestra by accident. We're called Orchestra because that is what it takes to bring these type of innovations to reality and to patients. Our orchestra looks a little different. We are, I'm proud to say, over 100 people in Orchestra today, working across R&D, both on the device side as well as on the pharma side.
You may think of us as a device company, but core to the technology we're going to talk about first is true innovation in how do you protect a drug that works wonderfully in the body for extended release and focal delivery. We have phenomenal people now in our clinical operation, our field clinical operation, that have driven the BACKBEAT trial and are driving the Virtue trial. Cutting across that are other skill sets, from marketing skill sets, regulatory, and finance. I am incredibly proud of the Orchestra organization that we've built. This organization then partners with amazing physicians, we have some with us today. Amazing research staff. We frankly see our patients, we underestimate the patients we are seeking to treat are a partner in the innovations that we are bringing forward.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProKeep exploring
